On the financial front, Rigel reported an expected total revenue of approximately $57.6 million for the fourth quarter of 2024, a substantial increase from the same period in 2023. The company's ...

The Rigel BP-SiM is a handheld NIBP simulator, incorporating a range of custom settings that include a variety of paediatric and adult NIBP pressure simulations, pulse volume adjustments ...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...

Rigel, which belongs to the Zacks Medical - Drugs industry, posted revenues of $57.6 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.02%. This compares to ...